CLL Phase 3 Study: Zanubrutinib Bests Ibrutinib ...Middle East

Medscape - News
The second-generation Bruton's tyrosine kinase inhibitor zanubrutinib outperformed ibrutinib in a phase 3 study in patients with chronic lymphocytic leukemia (CLL) . MDedge News

Hence then, the article about cll phase 3 study zanubrutinib bests ibrutinib was published today ( ) and is available on Medscape ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( CLL Phase 3 Study: Zanubrutinib Bests Ibrutinib )

Apple Storegoogle play

Last updated :

Also on site :



Latest News